基于网络药理学的中医药治疗非酒精性脂肪性肝病综述
本文通过检索PubMed、Web of Science和Embase等数据库,综述近年单味中药、中药组合及中成药治疗非酒精性脂肪性肝病的相关信号通路与具体作用机制。相关研究显示中医药具有多成分、多靶点、多通路的作用特点,为临床疗效提供支持,但网络药理学仍存在假阳性与假阴性等局限。
要点
- 网络药理学可构建「药-病-靶-通路」网络,用于预测中医药治疗NAFLD的分子机制。
- 单味中药、中药组合及中成药治疗NAFLD涉及多条信号通路与多靶点机制。
- 网络药理学与中医整体观及辨证论治思路相契合,但需排除假阳性与假阴性风险。
核心结论
- 网络药理学更符合中医治病思维,但存在局限,未来需排除假阳性与假阴性并开展更深入临床或实验研究。
研究设计与样本
- 综述类文章,通过检索PubMed、Web of Science和Embase等数据库,汇总近年单味中药、中药组合及中成药治疗NAFLD的相关信号通路与具体作用机制研究。
主要发现
- 相关研究充分展示中医药治疗NAFLD具有多成分、多靶点、多通路的作用特点,为中医药在临床发挥确切疗效提供有力支持。
临床怎么用
- 可将网络药理学作为探索中医药治疗NAFLD分子机制的辅助工具,但需注意其预测结果可能存在假阳性与假阴性。
局限性
- 网络药理学存在潜在假阳性与假阴性风险,成分、靶点与疾病之间的互连性尚需明确,仍需更深入临床或实验研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by abnormalities in hepatic fat deposition, the incidence of which has been increasing year by year in recent years. It has become the largest chronic liver disease globally and one of the important causes of cirrhosis and even primary liver cancer formation. The pathogenesis of NAFLD has not yet been fully clarified. Modern medicine lacks targeted clinical treatment protocols for NAFLD, and most drugs lack efficacy and have high side effects. In contrast, Traditional Chinese Medicine (TCM) has significant advantages in the treatment and prevention of NAFLD, which have been widely recognized by scholars around the world. In recent years, through the establishment of a "medicine-disease-target-pathway" network relationship, network pharmacology can explore the molecular basis of the role of medicines in disease prevention and treatment from various perspectives, predicting the pharmacological mechanism of the corresponding medicines. This approach is compatible with the holistic view and treatment based on pattern differentiation of TCM and has been widely used in TCM research. In this paper, by searching relevant databases such as PubMed, Web of Science, and Embase, we reviewed and analyzed the relevant signaling pathways and specific mechanisms of action of single Chinese medicine, Chinese medicine combinations, and Chinese patent medicine for the treatment of NAFLD in recent years. These related studies fully demonstrated the therapeutic characteristics of TCM with multi-components, multi-targets, and multi-pathways, which provided strong support for the exact efficacy of TCM exerted in the clinic. In conclusion, we believe that network pharmacology is more in line with the TCM mindset of treating diseases, but with some limitations. In the future, we should eliminate the potential risks of false positives and false negatives, clarify the interconnectivity between components, targets, and diseases, and conduct deeper clinical or experimental studies.
引用
- Zheng S, Xue C, Li S, et al. Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review. Front Pharmacol. 2024. PMID: 38694920. doi:10.3389/fphar.2024.1381712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。